Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic


30 Sep 2019


Poster Display session 3


Anjuleta Kampitsi


Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276


A. Kampitsi1, K. Papastergiou2, D. Owens3, E. Vlachou3, T. Haliamalias4, A. Vasilopanagi4, I. Tsatsou5, M. Lavdaniti6

Author affiliations

  • 1 One Day Chemotherapy Clinic, Oncology Hospital "O Agios Savas", 13678 - Thessaloniki/GR
  • 2 Surgery Clinic, Oncology Hospital "Theageneio", 57400 - Thessaloniki/GR
  • 3 Nursing Department, University of West Attica, 12243 - Athens/GR
  • 4 One Day Chemotherapy Clinic, Oncology Hospital "O Agios Savas", 13678 - Athens/GR
  • 5 One Day Chemotherapy Clinic, 251 Hellenic Airforce General Hospital, 115 25 - Athens/GR
  • 6 Nursing Department, Alexander Technological Educational Institute, 57400 - Thessaloniki/GR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3117


Cancer patients undergoing chemotherapy experienced many adverse effects. The purpose of this study was to assess the symptoms were experienced by cancer patients using the Edmonton Symptom Assessment scale.


The study was cross-sectional and was conducted in one-day clinic in large oncology hospital in capital of Greece. The sample consisted of 199 cancer patients undergoing chemotherapy in cycle 3. Date was collected using Edmonton Symptom Assessment Scale (ESAS) additionally with a questionnaire for demographic and clinical characteristics, Descriptive and conductive statistical methods were used.


The vast majority of patients were women (n = 153, 76.9%) and had breast cancer (n = 153, 76,9%). Patients experienced mild severity symptoms as could be seen from the mean values of symptoms (physical symptoms: 14.85±10.25, emotional symptoms: 6.84±5.24, well-being 3.73±2.61). There is a statistically significant difference between type of cancer and shortness of breath (p = 0.015) between gender and nausea (p = 0.013) gender and shortness of breath (p = 0.013). In addition, there is statistically difference between drowsiness and how is chemotherapy given (p = 0.0017). The rest of the comparisons revealed that there is a statistical significant difference between pain and type of chemotherapy regimen (p = 0.014), nausea and type of chemotherapy regimen (p = 0.012), well-being and type of chemotherapy regimen (p = 0.003) as well as between total symptoms and type of chemotherapy regimen (p = 0.025).


Edmonton Symptom Assessment Scale was an important clinical instrument for assessing symptoms in clinical practice. There is a need for further research in order to use this tool in a daily clinical practice in one day chemotherapy clinic.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.